Xencor, Inc. (NASDAQ:XNCR) - Wedbush boosted their FY2017 earnings estimates for shares of Xencor in a report released on Tuesday. Wedbush analyst D. Nierengarten now expects that the biopharmaceutical company will earn ($1.02) per share for the year, up from their prior estimate of ($1.16). Wedbush currently has a “Outperform” rating and a $29.00 target price on the stock. Wedbush also issued estimates for Xencor’s Q2 2018 earnings at ($0.42) EPS, FY2018 earnings at ($1.71) EPS, FY2019 earnings at ($1.90) EPS, FY2020 earnings at $1.00 EPS and FY2021 earnings at $0.81 EPS.
Other analysts also recently issued reports about the company. Zacks Investment Research downgraded Xencor from a “hold” rating to a “sell” rating in a research note on Friday. Canaccord Genuity reaffirmed a “buy” rating and issued a $36.00 target price on shares of Xencor in a research note on Tuesday. One research analyst has rated the stock with a sell rating, three have given a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $29.33.
Shares of Xencor (XNCR) traded up 0.09% during trading on Friday, hitting $21.30. 6,443 shares of the stock were exchanged. The firm has a 50 day moving average of $22.64 and a 200-day moving average of $23.06. The stock’s market cap is $999.52 million. Xencor has a 52-week low of $18.45 and a 52-week high of $29.38.
Xencor (NASDAQ:XNCR) last issued its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.15) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.25) by $0.10. The firm had revenue of $13.34 million for the quarter, compared to analyst estimates of $8.15 million. Xencor had a negative net margin of 121.04% and a negative return on equity of 13.79%.
In other Xencor news, major shareholder John S. Stafford III acquired 1,500 shares of the business’s stock in a transaction that occurred on Friday, June 16th. The stock was purchased at an average cost of $19.67 per share, with a total value of $29,505.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, major shareholder John S. Stafford III acquired 6,000 shares of the business’s stock in a transaction that occurred on Wednesday, June 28th. The shares were acquired at an average cost of $19.94 per share, with a total value of $119,640.00. The disclosure for this purchase can be found here. Insiders have sold a total of 34,766 shares of company stock valued at $739,408 over the last three months. Corporate insiders own 4.03% of the company’s stock.
Several hedge funds have recently modified their holdings of the company. Dimensional Fund Advisors LP increased its stake in shares of Xencor by 254.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 182,256 shares of the biopharmaceutical company’s stock worth $4,797,000 after buying an additional 130,778 shares during the last quarter. Norges Bank acquired a new stake in shares of Xencor during the fourth quarter worth about $15,601,000. Teachers Advisors LLC increased its stake in shares of Xencor by 2.0% in the fourth quarter. Teachers Advisors LLC now owns 319,914 shares of the biopharmaceutical company’s stock worth $8,420,000 after buying an additional 6,392 shares during the last quarter. Creative Planning increased its stake in shares of Xencor by 2.7% in the first quarter. Creative Planning now owns 38,400 shares of the biopharmaceutical company’s stock worth $919,000 after buying an additional 1,000 shares during the last quarter. Finally, Candriam Luxembourg S.C.A. increased its stake in shares of Xencor by 80.0% in the first quarter. Candriam Luxembourg S.C.A. now owns 135,000 shares of the biopharmaceutical company’s stock worth $3,229,000 after buying an additional 60,000 shares during the last quarter. 74.12% of the stock is owned by hedge funds and other institutional investors.
About Xencor
Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.
Receive News & Ratings for Xencor Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
